“With the receipt of FDA clearance for the BB-301 IND application this year and the pace of enrollment into the OPMD Natural History Study continuing to exceed our expectations, we are well positioned to begin the evaluation of BB-301 in subjects diagnosed with Oculopharyngeal Muscular Dystrophy,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “The Principal Investigator and the clinical team at the U.S. clinical trial site are finalizing the plan to dose the first study subject with BB-301 in December 2023 or January 2024. The strong interest from members of the Oculopharyngeal Muscular Dystrophy community, and the exceptional clinical trial execution by the U.S. clinical trial site, will support the generation of robust safety and efficacy data for BB-301 over the coming months.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNTC:
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
- BNTC Upcoming Earnings Report: What to Expect?
- Benitec Biopharma price target raised to $6 from $4 at JMP Securities
- Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
- Benitec Biopharma reports 2023 EPS ($14.12) vs. ($37.88) last year